Breaking News

Yesterday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Conference/Events	Terns Pharmaceuticals management to meet with Mizuho » 17:11 02/01/23 02/01 17:11 02/01/23 17:11 TERN Terns Pharmaceuticals $8.93 / -0.06 (-0.67%) Meeting to be held in New… Meeting to be held in New York on February 8 hosted by Mizuho. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events TERN Terns Pharmaceuticals $8.93 / -0.06 (-0.67%) 01/03/23 Suvretta Capital reports 7.0% passive stake in Terns Pharmaceuticals 12/23/22 Terns Pharmaceuticals director Lu acquires 758,620 common shares 12/20/22 Terns Pharmaceuticals reports inducement grants to new employees 11/04/22 Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501 TERN Terns Pharmaceuticals $8.93 / -0.06 (-0.67%) 01/16/23 Piper Sandler Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler 12/29/22 H.C. Wainwright Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright 09/27/22 Goldman Sachs Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs 09/12/22 H.C. Wainwright Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright TERN Terns Pharmaceuticals $8.93 / -0.06 (-0.67%) 11/09/22 Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c) 21 Dec TERN Terns Pharmaceuticals $8.93 / -0.06 (-0.67%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 12/27/22 Fly Insider: Terns, Air Transport among week's notable insider trades 12/19/22 Fly Intel: After-Hours Movers 02/08/23 Terns Pharmaceuticals
Syndicate	Terns Pharmaceuticals files $400M mixed securities shelf 16:28 02/01/23 02/01 16:28 02/01/23 16:28 TERN Terns Pharmaceuticals $8.93 / -0.06 (-0.67%) ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events TERN Terns Pharmaceuticals $8.93 / -0.06 (-0.67%) 01/03/23 Suvretta Capital reports 7.0% passive stake in Terns Pharmaceuticals 12/23/22 Terns Pharmaceuticals director Lu acquires 758,620 common shares 12/20/22 Terns Pharmaceuticals reports inducement grants to new employees 11/04/22 Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501 TERN Terns Pharmaceuticals $8.93 / -0.06 (-0.67%) 01/16/23 Piper Sandler Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler 12/29/22 H.C. Wainwright Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright 09/27/22 Goldman Sachs Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs 09/12/22 H.C. Wainwright Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright TERN Terns Pharmaceuticals $8.93 / -0.06 (-0.67%) 11/09/22 Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c) 21 Dec TERN Terns Pharmaceuticals $8.93 / -0.06 (-0.67%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 12/27/22 Fly Insider: Terns, Air Transport among week's notable insider trades 12/19/22 Fly Intel: After-Hours Movers 02/08/23 Terns Pharmaceuticals

Over a week ago
Conference/Events	Cantor Fitzgerald biotech analyst to hold analyst/industry conference call » 11:45 01/20/23 01/20 11:45 01/20/23 11:45 ARWR Arrowhead $33.52 / -0.42 (-1.24%) , TAK Takeda Pharmaceutical $16.28 / +0.08 (+0.49%) , ALGS Aligos Therapeutics $2.04 / -0.01 (-0.49%) , MDGL Madrigal Pharmaceuticals $295.67 / -3.53 (-1.18%) , VKTX Viking Therapeutics $8.56 / -0.15 (-1.72%) , TERN Terns Pharmaceuticals $8.23 / -0.16 (-1.91%) , AKRO Akero Therapeutics $46.87 / +0.72 (+1.56%) , ALT Altimmune $14.79 / -0.19 (-1.27%) Biotech Analyst Agrawal,… Biotech Analyst Agrawal, along with KOL Dr. Pierre Gholam, Medical Director of Liver Center of Excellence, University Hospitals of Cleveland, discuss Fazirsiran SEQUOIA data in AATD (Alpha-1 Antitrypsin Deficiency) and review NASH (Nonalcoholic Steatohepatitis) drugs on an Analyst/Industry conference call to be held on January 20 at 12 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VKTX TERN TAK MDGL ARWR ALT ALGS AKRO VKTX Viking Therapeutics $8.56 / -0.15 (-1.72%) 01/09/23 Viking Therapeutics completes enrollment in Phase 2b VOYAGE study of VK2809 01/02/23 Ascletis says Viking Therapeutics complaints 'have no merit' TERN Terns Pharmaceuticals $8.23 / -0.16 (-1.91%) 01/03/23 Suvretta Capital reports 7.0% passive stake in Terns Pharmaceuticals 12/23/22 Terns Pharmaceuticals director Lu acquires 758,620 common shares 12/20/22 Terns Pharmaceuticals reports inducement grants to new employees 11/04/22 Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501 TAK Takeda Pharmaceutical $16.28 / +0.08 (+0.49%) 01/18/23 Cryoport announces new strategic partnership with Syneos Health 01/05/23 Takeda Pharmaceutical reports 'favorable' results from Phase 3 TAK-755 trial 12/19/22 Takeda reports Phase 3 AURORA trial did not meet primary endpoint MDGL Madrigal Pharmaceuticals $295.67 / -3.53 (-1.18%) 01/06/23 Madrigal announces additional results from Phase 2 MAESTRO-NASH trial 12/19/22 Viking Therapeutics up 58% after Madrigal announces NASH trial data 12/19/22 Madrigal jumps 217% to $202.28 after NASH study hits endpoints 12/19/22 Madrigal Pharmaceuticals announces results from Phase 3 MAESTRO-NASH trial ARWR Arrowhead $33.52 / -0.42 (-1.24%) 01/09/23 Takeda Pharmaceutical, Arrowhead announce topline results from SEQUOIA study 12/20/22 Arrowhead announces $25M milestone payment from Amgen 12/08/22 Horizon Therapeutics announces first subject does in HZN-457 trial 11/09/22 Royalty Pharma agrees to acquire royalty interest in olpasiran from Arrowhead ALT Altimmune $14.79 / -0.19 (-1.27%) 01/04/23 Altimmune appoints Jordt as Chief Business Officer 12/20/22 Altimmune announces topline results from 24-week trial of pemvidutide 09/28/22 Altimmune announces first dosing of all subjects in Phase 2 MOMENTUM trial 09/14/22 Altimmune down 58% in pre-market after results of Phase 1b study of pemvidutide ALGS Aligos Therapeutics $2.04 / -0.01 (-0.49%) 01/05/23 Aligos on track to complete Phase 2-enabling activities in 2023 for ALG-055009 12/14/22 Aligos Therapeutics initiates dosing in ALG-125755 trial 12/08/22 Aligos presents nonclinical data for coronavirus therapeutic program 11/04/22 Aligos Therapeutics presents data for its Capsid Assembly Modulator AKRO Akero Therapeutics $46.87 / +0.72 (+1.56%) 01/18/23 Officer of Akero Therapeutics Yale sells $253K in company shares 01/10/23 Akero Therapeutics appoints Patrick Lamy as SVP, commercial strategyIovance Biotherapeutics 12/21/22 Akero completes enrollment in Phase 2b efruxifermin study for treatment of NASH 12/08/22 Akero Therapeutics announces efruxifermin granted BTD from U.S. FDA ARWR TAK ALGS MDGL VKTX TERN AKRO ALT ARWR Arrowhead $33.52 / -0.42 (-1.24%) 01/10/23 Chardan Arrowhead price target lowered to $60 from $82 at Chardan 01/09/23 Piper Sandler Arrowhead price target lowered to $55 from $64 at Piper Sandler 12/20/22 Piper Sandler Piper recommends 'down market cap' biotech exposure for 2023 12/20/22 Piper Sandler Piper Sandler names three top biotechnology picks for 2023 TAK Takeda Pharmaceutical $16.28 / +0.08 (+0.49%) 01/03/23 Wells Fargo Ascendis Pharma price target raised to $177 from $169 at Wells Fargo 12/13/22 Piper Sandler Takeda deal has positive read through for Ventyx, says Piper 11/11/22 BTIG Poseida Therapeutics price target lowered to $14 from $20 at BTIG 10/05/22 H.C. Wainwright H.C. Wainwright has more confidence in Astria opportunity after KalVista news ALGS Aligos Therapeutics $2.04 / -0.01 (-0.49%) 01/16/23 Piper Sandler Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler 01/06/23 Piper Sandler Aligos upgraded to Overweight at Piper after peer's 'highly encouraging' data 01/06/23 Piper Sandler Aligos Therapeutics upgraded to Overweight from Neutral at Piper Sandler 01/06/23 Jefferies Jefferies upgrades Aligos to Buy on derisking of NASH pill MDGL Madrigal Pharmaceuticals $295.67 / -3.53 (-1.18%) 01/06/23 Canaccord Madrigal Pharmaceuticals price target raised to $296 from $270 at Canaccord VKTX Viking Therapeutics $8.56 / -0.15 (-1.72%) 12/20/22 Maxim Viking Therapeutics price target raised to $15 from $10 at Maxim 12/19/22 Maxim Viking Therapeutics price target raised to $15 from $10 at Maxim 12/19/22 Raymond James Raymond James upgrades Madrigal to Market Perform after NASH data TERN Terns Pharmaceuticals $8.23 / -0.16 (-1.91%) 12/29/22 H.C. Wainwright Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright 09/27/22 Goldman Sachs Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs 09/12/22 H.C. Wainwright Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright AKRO Akero Therapeutics $46.87 / +0.72 (+1.56%) 12/20/22 Evercore ISI Madrigal Pharmaceuticals price target raised to $325 from $175 at Evercore ISI 12/19/22 Morgan Stanley Akero's efruxifermin efficacy still compares favorably, says Morgan Stanley 11/14/22 Cantor Fitzgerald 89bio price target raised to $34 from $27 at Cantor Fitzgerald 11/11/22 RBC Capital 89bio price target lowered to $29 from $35 at RBC Capital ALT Altimmune $14.79 / -0.19 (-1.27%) 01/18/23 Evercore ISI Altimmune price target raised to $25 from $14 at Evercore ISI 12/20/22 Piper Sandler Altimmune 24-week NAFLD data 'strong and encouraging,' says Piper Sandler 12/01/22 Goldman Sachs Altimmune initiated with a Buy at Goldman Sachs 09/16/22 Guggenheim Altimmune price target lowered to $26 from $31 at Guggenheim VKTX TERN MDGL ARWR ALT ALGS AKRO VKTX Viking Therapeutics $8.56 / -0.15 (-1.72%) 10/26/22 Viking Therapeutics reports Q3 EPS (21c), consensus (23c) 07/27/22 Viking Therapeutics reports Q2 EPS (23c), consensus (21c) TERN Terns Pharmaceuticals $8.23 / -0.16 (-1.91%) 11/09/22 Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c) MDGL Madrigal Pharmaceuticals $295.67 / -3.53 (-1.18%) 11/03/22 Madrigal Pharmaceuticals reports Q3 EPS ($4.15), consensus ($4.75) 08/04/22 Madrigal Pharmaceuticals reports Q2 EPS ($4.14) vs ($3.72) last year ARWR Arrowhead $33.52 / -0.42 (-1.24%) 11/28/22 Arrowhead reports FY22 EPS ($1.67), consensus ($1.03) 08/04/22 Arrowhead reports Q3 EPS (68c), consensus (51c) ALT Altimmune $14.79 / -0.19 (-1.27%) 11/10/22 Altimmune reports Q3 EPS (48c), consensus (50c) 08/11/22 Altimmune reports Q2 EPS (42c) vs (60c) last year ALGS Aligos Therapeutics $2.04 / -0.01 (-0.49%) 11/02/22 Aligos Therapeutics reports Q3 EPS (44c), consensus (58c) AKRO Akero Therapeutics $46.87 / +0.72 (+1.56%) 11/04/22 Akero Therapeutics reports Q3 EPS (92c), consensus (74c) 08/04/22 Akero Therapeutics reports Q2 EPS (77c), consensus (86c) 21 Dec 15 Sep VKTX TAK VKTX Viking Therapeutics $8.56 / -0.15 (-1.72%) 01/02/23 Viking sued Ascletis alleging stolen trade secrets, Reuters reports TAK Takeda Pharmaceutical $16.28 / +0.08 (+0.49%) 08/30/22 Takeda eyes global vaccine market following Qdenga approval, FT reports VKTX TERN MDGL ALT ALGS AKRO VKTX Viking Therapeutics $8.56 / -0.15 (-1.72%) 12/19/22 Trial success is rocketing this NASH stock higher and sinking these peers TERN Terns Pharmaceuticals $8.23 / -0.16 (-1.91%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 12/27/22 Fly Insider: Terns, Air Transport among week's notable insider trades 12/19/22 Fly Intel: After-Hours Movers MDGL Madrigal Pharmaceuticals $295.67 / -3.53 (-1.18%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 12/19/22 What You Missed On Wall Street On Monday 12/19/22 What You Missed On Wall Street This Morning ALT Altimmune $14.79 / -0.19 (-1.27%) 12/20/22 Fly Intel: Pre-market Movers 09/14/22 What You Missed On Wall Street On Wednesday 09/14/22 What You Missed On Wall Street This Morning ALGS Aligos Therapeutics $2.04 / -0.01 (-0.49%) 01/06/23 What You Missed On Wall Street On Friday 01/06/23 What You Missed On Wall Street This Morning AKRO Akero Therapeutics $46.87 / +0.72 (+1.56%) 09/13/22 What You Missed On Wall Street On Tuesday 09/13/22 What You Missed On Wall Street This Morning 09/13/22 Fly Intel: Pre-market Movers 01/20/23 Biotechnology 02/10/23 Biotechnology 02/24/23 Annual Meeting of AAAAI 2023 01/20/23 Altimmune VKTX MDGL ALT AKRO VKTX Viking Therapeutics $8.56 / -0.15 (-1.72%) 01/06/23 Viking Therapeutics call volume above normal and directionally bullish MDGL Madrigal Pharmaceuticals $295.67 / -3.53 (-1.18%) 12/23/22 Largest borrow rate increases among liquid names 12/21/22 Madrigal Pharmaceuticals put volume heavy and directionally bearish 12/05/22 Madrigal Pharmaceuticals put volume heavy and directionally bearish ALT Altimmune $14.79 / -0.19 (-1.27%) 09/13/22 Altimmune call volume above normal and directionally bullish 09/12/22 Altimmune put volume heavy and directionally bearish AKRO Akero Therapeutics $46.87 / +0.72 (+1.56%) 10/26/22 Largest borrow rate increases among liquid names
Conference/Events	Cantor Fitzgerald biotech analyst to hold analyst/industry conference call » 04:55 01/20/23 01/20 04:55 01/20/23 04:55 ARWR Arrowhead $33.94 / -2.05 (-5.70%) , TAK Takeda Pharmaceutical $16.20 / +0.055 (+0.34%) , ALGS Aligos Therapeutics $2.05 / -0.05 (-2.38%) , MDGL Madrigal Pharmaceuticals $299.60 / -0.35 (-0.12%) , VKTX Viking Therapeutics $8.71 / -0.44 (-4.81%) , TERN Terns Pharmaceuticals $8.35 / +0.12 (+1.46%) , AKRO Akero Therapeutics $46.16 / -0.63 (-1.35%) , ALT Altimmune $14.96 / +0.01 (+0.07%) Biotech Analyst Agrawal,… Biotech Analyst Agrawal, along with KOL Dr. Pierre Gholam, Medical Director of Liver Center of Excellence, University Hospitals of Cleveland, discuss Fazirsiran SEQUOIA data in AATD (Alpha-1 Antitrypsin Deficiency) and review NASH (Nonalcoholic Steatohepatitis) drugs on an Analyst/Industry conference call to be held on January 20 at 12 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VKTX TERN TAK MDGL ARWR ALT ALGS AKRO VKTX Viking Therapeutics $8.71 / -0.44 (-4.81%) 01/09/23 Viking Therapeutics completes enrollment in Phase 2b VOYAGE study of VK2809 01/02/23 Ascletis says Viking Therapeutics complaints 'have no merit' TERN Terns Pharmaceuticals $8.35 / +0.12 (+1.46%) 01/03/23 Suvretta Capital reports 7.0% passive stake in Terns Pharmaceuticals 12/23/22 Terns Pharmaceuticals director Lu acquires 758,620 common shares 12/20/22 Terns Pharmaceuticals reports inducement grants to new employees 11/04/22 Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501 TAK Takeda Pharmaceutical $16.20 / +0.055 (+0.34%) 01/18/23 Cryoport announces new strategic partnership with Syneos Health 01/05/23 Takeda Pharmaceutical reports 'favorable' results from Phase 3 TAK-755 trial 12/19/22 Takeda reports Phase 3 AURORA trial did not meet primary endpoint MDGL Madrigal Pharmaceuticals $299.60 / -0.35 (-0.12%) 01/06/23 Madrigal announces additional results from Phase 2 MAESTRO-NASH trial 12/19/22 Viking Therapeutics up 58% after Madrigal announces NASH trial data 12/19/22 Madrigal jumps 217% to $202.28 after NASH study hits endpoints 12/19/22 Madrigal Pharmaceuticals announces results from Phase 3 MAESTRO-NASH trial ARWR Arrowhead $33.94 / -2.05 (-5.70%) 01/09/23 Takeda Pharmaceutical, Arrowhead announce topline results from SEQUOIA study 12/20/22 Arrowhead announces $25M milestone payment from Amgen 12/08/22 Horizon Therapeutics announces first subject does in HZN-457 trial 11/09/22 Royalty Pharma agrees to acquire royalty interest in olpasiran from Arrowhead ALT Altimmune $14.96 / +0.01 (+0.07%) 01/04/23 Altimmune appoints Jordt as Chief Business Officer 12/20/22 Altimmune announces topline results from 24-week trial of pemvidutide 09/28/22 Altimmune announces first dosing of all subjects in Phase 2 MOMENTUM trial 09/14/22 Altimmune down 58% in pre-market after results of Phase 1b study of pemvidutide ALGS Aligos Therapeutics $2.05 / -0.05 (-2.38%) 01/05/23 Aligos on track to complete Phase 2-enabling activities in 2023 for ALG-055009 12/14/22 Aligos Therapeutics initiates dosing in ALG-125755 trial 12/08/22 Aligos presents nonclinical data for coronavirus therapeutic program 11/04/22 Aligos Therapeutics presents data for its Capsid Assembly Modulator AKRO Akero Therapeutics $46.16 / -0.63 (-1.35%) 01/18/23 Officer of Akero Therapeutics Yale sells $253K in company shares 01/10/23 Akero Therapeutics appoints Patrick Lamy as SVP, commercial strategyIovance Biotherapeutics 12/21/22 Akero completes enrollment in Phase 2b efruxifermin study for treatment of NASH 12/08/22 Akero Therapeutics announces efruxifermin granted BTD from U.S. FDA ARWR TAK ALGS MDGL VKTX TERN AKRO ALT ARWR Arrowhead $33.94 / -2.05 (-5.70%) 01/10/23 Chardan Arrowhead price target lowered to $60 from $82 at Chardan 01/09/23 Piper Sandler Arrowhead price target lowered to $55 from $64 at Piper Sandler 12/20/22 Piper Sandler Piper recommends 'down market cap' biotech exposure for 2023 12/20/22 Piper Sandler Piper Sandler names three top biotechnology picks for 2023 TAK Takeda Pharmaceutical $16.20 / +0.055 (+0.34%) 01/03/23 Wells Fargo Ascendis Pharma price target raised to $177 from $169 at Wells Fargo 12/13/22 Piper Sandler Takeda deal has positive read through for Ventyx, says Piper 11/11/22 BTIG Poseida Therapeutics price target lowered to $14 from $20 at BTIG 10/05/22 H.C. Wainwright H.C. Wainwright has more confidence in Astria opportunity after KalVista news ALGS Aligos Therapeutics $2.05 / -0.05 (-2.38%) 01/16/23 Piper Sandler Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler 01/06/23 Piper Sandler Aligos upgraded to Overweight at Piper after peer's 'highly encouraging' data 01/06/23 Piper Sandler Aligos Therapeutics upgraded to Overweight from Neutral at Piper Sandler 01/06/23 Jefferies Jefferies upgrades Aligos to Buy on derisking of NASH pill MDGL Madrigal Pharmaceuticals $299.60 / -0.35 (-0.12%) 01/06/23 Canaccord Madrigal Pharmaceuticals price target raised to $296 from $270 at Canaccord VKTX Viking Therapeutics $8.71 / -0.44 (-4.81%) 12/20/22 Maxim Viking Therapeutics price target raised to $15 from $10 at Maxim 12/19/22 Maxim Viking Therapeutics price target raised to $15 from $10 at Maxim 12/19/22 Raymond James Raymond James upgrades Madrigal to Market Perform after NASH data TERN Terns Pharmaceuticals $8.35 / +0.12 (+1.46%) 12/29/22 H.C. Wainwright Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright 09/27/22 Goldman Sachs Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs 09/12/22 H.C. Wainwright Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright AKRO Akero Therapeutics $46.16 / -0.63 (-1.35%) 12/20/22 Evercore ISI Madrigal Pharmaceuticals price target raised to $325 from $175 at Evercore ISI 12/19/22 Morgan Stanley Akero's efruxifermin efficacy still compares favorably, says Morgan Stanley 11/14/22 Cantor Fitzgerald 89bio price target raised to $34 from $27 at Cantor Fitzgerald 11/11/22 RBC Capital 89bio price target lowered to $29 from $35 at RBC Capital ALT Altimmune $14.96 / +0.01 (+0.07%) 01/18/23 Evercore ISI Altimmune price target raised to $25 from $14 at Evercore ISI 12/20/22 Piper Sandler Altimmune 24-week NAFLD data 'strong and encouraging,' says Piper Sandler 12/01/22 Goldman Sachs Altimmune initiated with a Buy at Goldman Sachs 09/16/22 Guggenheim Altimmune price target lowered to $26 from $31 at Guggenheim VKTX TERN MDGL ARWR ALT ALGS AKRO VKTX Viking Therapeutics $8.71 / -0.44 (-4.81%) 10/26/22 Viking Therapeutics reports Q3 EPS (21c), consensus (23c) 07/27/22 Viking Therapeutics reports Q2 EPS (23c), consensus (21c) TERN Terns Pharmaceuticals $8.35 / +0.12 (+1.46%) 11/09/22 Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c) MDGL Madrigal Pharmaceuticals $299.60 / -0.35 (-0.12%) 11/03/22 Madrigal Pharmaceuticals reports Q3 EPS ($4.15), consensus ($4.75) 08/04/22 Madrigal Pharmaceuticals reports Q2 EPS ($4.14) vs ($3.72) last year ARWR Arrowhead $33.94 / -2.05 (-5.70%) 11/28/22 Arrowhead reports FY22 EPS ($1.67), consensus ($1.03) 08/04/22 Arrowhead reports Q3 EPS (68c), consensus (51c) ALT Altimmune $14.96 / +0.01 (+0.07%) 11/10/22 Altimmune reports Q3 EPS (48c), consensus (50c) 08/11/22 Altimmune reports Q2 EPS (42c) vs (60c) last year ALGS Aligos Therapeutics $2.05 / -0.05 (-2.38%) 11/02/22 Aligos Therapeutics reports Q3 EPS (44c), consensus (58c) AKRO Akero Therapeutics $46.16 / -0.63 (-1.35%) 11/04/22 Akero Therapeutics reports Q3 EPS (92c), consensus (74c) 08/04/22 Akero Therapeutics reports Q2 EPS (77c), consensus (86c) 21 Dec 15 Sep VKTX TAK VKTX Viking Therapeutics $8.71 / -0.44 (-4.81%) 01/02/23 Viking sued Ascletis alleging stolen trade secrets, Reuters reports TAK Takeda Pharmaceutical $16.20 / +0.055 (+0.34%) 08/30/22 Takeda eyes global vaccine market following Qdenga approval, FT reports VKTX TERN MDGL ALT ALGS AKRO VKTX Viking Therapeutics $8.71 / -0.44 (-4.81%) 12/19/22 Trial success is rocketing this NASH stock higher and sinking these peers TERN Terns Pharmaceuticals $8.35 / +0.12 (+1.46%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 12/27/22 Fly Insider: Terns, Air Transport among week's notable insider trades 12/19/22 Fly Intel: After-Hours Movers MDGL Madrigal Pharmaceuticals $299.60 / -0.35 (-0.12%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 12/19/22 What You Missed On Wall Street On Monday 12/19/22 What You Missed On Wall Street This Morning ALT Altimmune $14.96 / +0.01 (+0.07%) 12/20/22 Fly Intel: Pre-market Movers 09/14/22 What You Missed On Wall Street On Wednesday 09/14/22 What You Missed On Wall Street This Morning ALGS Aligos Therapeutics $2.05 / -0.05 (-2.38%) 01/06/23 What You Missed On Wall Street On Friday 01/06/23 What You Missed On Wall Street This Morning AKRO Akero Therapeutics $46.16 / -0.63 (-1.35%) 09/13/22 What You Missed On Wall Street On Tuesday 09/13/22 What You Missed On Wall Street This Morning 09/13/22 Fly Intel: Pre-market Movers 01/20/23 Biotechnology 02/10/23 Biotechnology 02/24/23 Annual Meeting of AAAAI 2023 01/20/23 Altimmune VKTX MDGL ALT AKRO VKTX Viking Therapeutics $8.71 / -0.44 (-4.81%) 01/06/23 Viking Therapeutics call volume above normal and directionally bullish MDGL Madrigal Pharmaceuticals $299.60 / -0.35 (-0.12%) 12/23/22 Largest borrow rate increases among liquid names 12/21/22 Madrigal Pharmaceuticals put volume heavy and directionally bearish 12/05/22 Madrigal Pharmaceuticals put volume heavy and directionally bearish ALT Altimmune $14.96 / +0.01 (+0.07%) 09/13/22 Altimmune call volume above normal and directionally bullish 09/12/22 Altimmune put volume heavy and directionally bearish AKRO Akero Therapeutics $46.16 / -0.63 (-1.35%) 10/26/22 Largest borrow rate increases among liquid names
Conference/Events	Cantor Fitzgerald biotech analyst to hold analyst/industry conference call » 14:37 01/17/23 01/17 14:37 01/17/23 14:37 ARWR Arrowhead $36.75 / -0.095 (-0.26%) , TAK Takeda Pharmaceutical $16.13 / +0.04 (+0.25%) , ALGS Aligos Therapeutics $2.00 / +0.36 (+21.95%) , MDGL Madrigal Pharmaceuticals $294.66 / -4.615 (-1.54%) , VKTX Viking Therapeutics $9.05 / +0.1 (+1.12%) , TERN Terns Pharmaceuticals $8.76 / -0.56 (-6.01%) , AKRO Akero Therapeutics $48.30 / -1.97 (-3.92%) , ALT Altimmune $15.21 / -1.075 (-6.60%) Biotech Analyst Agrawal,… Biotech Analyst Agrawal, along with KOL Dr. Pierre Gholam, Medical Director of Liver Center of Excellence, University Hospitals of Cleveland, discuss Fazirsiran SEQUOIA data in AATD (Alpha-1 Antitrypsin Deficiency) and review NASH (Nonalcoholic Steatohepatitis) drugs on an Analyst/Industry conference call to be held on January 20 at 12 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VKTX TERN TAK MDGL ARWR ALT ALGS AKRO VKTX Viking Therapeutics $9.05 / +0.1 (+1.12%) 01/09/23 Viking Therapeutics completes enrollment in Phase 2b VOYAGE study of VK2809 01/02/23 Ascletis says Viking Therapeutics complaints 'have no merit' 07/19/22 Viking Therapeutics: FDA lifts clinical hold on Phase 1b trial of VK0214 TERN Terns Pharmaceuticals $8.76 / -0.56 (-6.01%) 01/03/23 Suvretta Capital reports 7.0% passive stake in Terns Pharmaceuticals 12/23/22 Terns Pharmaceuticals director Lu acquires 758,620 common shares 12/20/22 Terns Pharmaceuticals reports inducement grants to new employees 11/04/22 Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501 TAK Takeda Pharmaceutical $16.13 / +0.04 (+0.25%) 01/05/23 Takeda Pharmaceutical reports 'favorable' results from Phase 3 TAK-755 trial 12/19/22 Takeda reports Phase 3 AURORA trial did not meet primary endpoint 12/13/22 Takeda to acquire NDI-034858 from Nimbus Therapeutics for $4B upfront MDGL Madrigal Pharmaceuticals $294.66 / -4.615 (-1.54%) 01/06/23 Madrigal announces additional results from Phase 2 MAESTRO-NASH trial 12/19/22 Viking Therapeutics up 58% after Madrigal announces NASH trial data 12/19/22 Madrigal jumps 217% to $202.28 after NASH study hits endpoints 12/19/22 Madrigal Pharmaceuticals announces results from Phase 3 MAESTRO-NASH trial ARWR Arrowhead $36.75 / -0.095 (-0.26%) 01/09/23 Takeda Pharmaceutical, Arrowhead announce topline results from SEQUOIA study 12/20/22 Arrowhead announces $25M milestone payment from Amgen 12/08/22 Horizon Therapeutics announces first subject does in HZN-457 trial 11/09/22 Royalty Pharma agrees to acquire royalty interest in olpasiran from Arrowhead ALT Altimmune $15.21 / -1.075 (-6.60%) 01/04/23 Altimmune appoints Jordt as Chief Business Officer 12/20/22 Altimmune announces topline results from 24-week trial of pemvidutide 09/28/22 Altimmune announces first dosing of all subjects in Phase 2 MOMENTUM trial 09/14/22 Altimmune down 58% in pre-market after results of Phase 1b study of pemvidutide ALGS Aligos Therapeutics $2.00 / +0.36 (+21.95%) 01/05/23 Aligos on track to complete Phase 2-enabling activities in 2023 for ALG-055009 12/14/22 Aligos Therapeutics initiates dosing in ALG-125755 trial 12/08/22 Aligos presents nonclinical data for coronavirus therapeutic program 11/04/22 Aligos Therapeutics presents data for its Capsid Assembly Modulator AKRO Akero Therapeutics $48.30 / -1.97 (-3.92%) 01/10/23 Akero Therapeutics appoints Patrick Lamy as SVP, commercial strategyIovance Biotherapeutics 12/21/22 Akero completes enrollment in Phase 2b efruxifermin study for treatment of NASH 12/08/22 Akero Therapeutics announces efruxifermin granted BTD from U.S. FDA 11/04/22 Akero Therapeutics announces anticipated milestones in 2023 ARWR TAK ALGS MDGL VKTX TERN AKRO ALT ARWR Arrowhead $36.75 / -0.095 (-0.26%) 01/10/23 Chardan Arrowhead price target lowered to $60 from $82 at Chardan 01/09/23 Piper Sandler Arrowhead price target lowered to $55 from $64 at Piper Sandler 12/20/22 Piper Sandler Piper recommends 'down market cap' biotech exposure for 2023 12/20/22 Piper Sandler Piper Sandler names three top biotechnology picks for 2023 TAK Takeda Pharmaceutical $16.13 / +0.04 (+0.25%) 01/03/23 Wells Fargo Ascendis Pharma price target raised to $177 from $169 at Wells Fargo 12/13/22 Piper Sandler Takeda deal has positive read through for Ventyx, says Piper 11/11/22 BTIG Poseida Therapeutics price target lowered to $14 from $20 at BTIG 10/05/22 H.C. Wainwright H.C. Wainwright has more confidence in Astria opportunity after KalVista news ALGS Aligos Therapeutics $2.00 / +0.36 (+21.95%) 01/16/23 Piper Sandler Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler 01/06/23 Piper Sandler Aligos upgraded to Overweight at Piper after peer's 'highly encouraging' data 01/06/23 Piper Sandler Aligos Therapeutics upgraded to Overweight from Neutral at Piper Sandler 01/06/23 Jefferies Jefferies upgrades Aligos to Buy on derisking of NASH pill MDGL Madrigal Pharmaceuticals $294.66 / -4.615 (-1.54%) 01/06/23 Canaccord Madrigal Pharmaceuticals price target raised to $296 from $270 at Canaccord VKTX Viking Therapeutics $9.05 / +0.1 (+1.12%) 12/20/22 Maxim Viking Therapeutics price target raised to $15 from $10 at Maxim 12/19/22 Maxim Viking Therapeutics price target raised to $15 from $10 at Maxim 12/19/22 Raymond James Raymond James upgrades Madrigal to Market Perform after NASH data TERN Terns Pharmaceuticals $8.76 / -0.56 (-6.01%) 12/29/22 H.C. Wainwright Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright 09/27/22 Goldman Sachs Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs 09/12/22 H.C. Wainwright Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright AKRO Akero Therapeutics $48.30 / -1.97 (-3.92%) 12/20/22 Evercore ISI Madrigal Pharmaceuticals price target raised to $325 from $175 at Evercore ISI 12/19/22 Morgan Stanley Akero's efruxifermin efficacy still compares favorably, says Morgan Stanley 11/14/22 Cantor Fitzgerald 89bio price target raised to $34 from $27 at Cantor Fitzgerald 11/11/22 RBC Capital 89bio price target lowered to $29 from $35 at RBC Capital ALT Altimmune $15.21 / -1.075 (-6.60%) 12/20/22 Piper Sandler Altimmune 24-week NAFLD data 'strong and encouraging,' says Piper Sandler 12/01/22 Goldman Sachs Altimmune initiated with a Buy at Goldman Sachs 09/16/22 Guggenheim Altimmune price target lowered to $26 from $31 at Guggenheim 09/16/22 H.C. Wainwright Altimmune selloff post Phase 1 data overdone, says H.C. Wainwright VKTX TERN MDGL ARWR ALT ALGS AKRO VKTX Viking Therapeutics $9.05 / +0.1 (+1.12%) 10/26/22 Viking Therapeutics reports Q3 EPS (21c), consensus (23c) 07/27/22 Viking Therapeutics reports Q2 EPS (23c), consensus (21c) TERN Terns Pharmaceuticals $8.76 / -0.56 (-6.01%) 11/09/22 Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c) MDGL Madrigal Pharmaceuticals $294.66 / -4.615 (-1.54%) 11/03/22 Madrigal Pharmaceuticals reports Q3 EPS ($4.15), consensus ($4.75) 08/04/22 Madrigal Pharmaceuticals reports Q2 EPS ($4.14) vs ($3.72) last year ARWR Arrowhead $36.75 / -0.095 (-0.26%) 11/28/22 Arrowhead reports FY22 EPS ($1.67), consensus ($1.03) 08/04/22 Arrowhead reports Q3 EPS (68c), consensus (51c) ALT Altimmune $15.21 / -1.075 (-6.60%) 11/10/22 Altimmune reports Q3 EPS (48c), consensus (50c) 08/11/22 Altimmune reports Q2 EPS (42c) vs (60c) last year ALGS Aligos Therapeutics $2.00 / +0.36 (+21.95%) 11/02/22 Aligos Therapeutics reports Q3 EPS (44c), consensus (58c) AKRO Akero Therapeutics $48.30 / -1.97 (-3.92%) 11/04/22 Akero Therapeutics reports Q3 EPS (92c), consensus (74c) 08/04/22 Akero Therapeutics reports Q2 EPS (77c), consensus (86c) 21 Dec 15 Sep VKTX TAK VKTX Viking Therapeutics $9.05 / +0.1 (+1.12%) 01/02/23 Viking sued Ascletis alleging stolen trade secrets, Reuters reports TAK Takeda Pharmaceutical $16.13 / +0.04 (+0.25%) 08/30/22 Takeda eyes global vaccine market following Qdenga approval, FT reports VKTX TERN MDGL ALT ALGS AKRO VKTX Viking Therapeutics $9.05 / +0.1 (+1.12%) 12/19/22 Trial success is rocketing this NASH stock higher and sinking these peers TERN Terns Pharmaceuticals $8.76 / -0.56 (-6.01%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 12/27/22 Fly Insider: Terns, Air Transport among week's notable insider trades 12/19/22 Fly Intel: After-Hours Movers MDGL Madrigal Pharmaceuticals $294.66 / -4.615 (-1.54%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 12/19/22 What You Missed On Wall Street On Monday 12/19/22 What You Missed On Wall Street This Morning ALT Altimmune $15.21 / -1.075 (-6.60%) 12/20/22 Fly Intel: Pre-market Movers 09/14/22 What You Missed On Wall Street On Wednesday 09/14/22 What You Missed On Wall Street This Morning ALGS Aligos Therapeutics $2.00 / +0.36 (+21.95%) 01/06/23 What You Missed On Wall Street On Friday 01/06/23 What You Missed On Wall Street This Morning AKRO Akero Therapeutics $48.30 / -1.97 (-3.92%) 09/13/22 What You Missed On Wall Street On Tuesday 09/13/22 What You Missed On Wall Street This Morning 09/13/22 Fly Intel: Pre-market Movers 02/10/23 Biotechnology 01/17/23 Advanced Therapies Week 01/18/23 3rd Annual B. Riley Securities Oncology Virtual Conference 02/24/23 Annual Meeting of AAAAI 2023 VKTX MDGL ALT AKRO VKTX Viking Therapeutics $9.05 / +0.1 (+1.12%) 01/06/23 Viking Therapeutics call volume above normal and directionally bullish MDGL Madrigal Pharmaceuticals $294.66 / -4.615 (-1.54%) 12/23/22 Largest borrow rate increases among liquid names 12/21/22 Madrigal Pharmaceuticals put volume heavy and directionally bearish 12/05/22 Madrigal Pharmaceuticals put volume heavy and directionally bearish ALT Altimmune $15.21 / -1.075 (-6.60%) 09/13/22 Altimmune call volume above normal and directionally bullish 09/12/22 Altimmune put volume heavy and directionally bearish AKRO Akero Therapeutics $48.30 / -1.97 (-3.92%) 10/26/22 Largest borrow rate increases among liquid names
Recommendations	Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler » 18:49 01/16/23 01/16 18:49 01/16/23 18:49 ALGS Aligos Therapeutics $1.64 / +0.18 (+12.33%) , VKTX Viking Therapeutics $8.95 / +0.17 (+1.94%) , TERN Terns Pharmaceuticals $9.12 / +0.035 (+0.39%) , MDGL Madrigal Pharmaceuticals $299.80 / -0.355 (-0.12%) Piper Sandler analyst… Piper Sandler analyst Yasmeen Rahimi raised the firm's price target on Aligos Therapeutics (ALGS) to $7 from $3 and keeps an Overweight rating on the shares. The analyst notes that the stock is trading below cash and thus, in her view, represents an untapped opportunity to own ahead of the major 2023-year in NASH. To support this, last week Rahimi attended NASH TAG and walked away with key nuances around excitement for the prospect of new NASH drugs with validated MoAs in the space. Accordingly, since topline Madrigal Pharmaceuticals (MDGL) MAESTRO-NASH data validated the THR-ss MoA by hitting on both primary endpoints, Viking Therapeutics (VKTX) was up 144% and Terns Pharmaceuticals (TERN) was up 58%, in the analyst's view leaving Aligos as the diamond-in-the-rough with a differentiated THR-ss asset. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options VKTX TERN MDGL ALGS VKTX Viking Therapeutics $8.95 / +0.17 (+1.94%) 01/09/23 Viking Therapeutics completes enrollment in Phase 2b VOYAGE study of VK2809 01/02/23 Ascletis says Viking Therapeutics complaints 'have no merit' 12/19/22 Viking Therapeutics up 58% after Madrigal announces NASH trial data 07/19/22 Viking Therapeutics: FDA lifts clinical hold on Phase 1b trial of VK0214 TERN Terns Pharmaceuticals $9.12 / +0.035 (+0.39%) 01/03/23 Suvretta Capital reports 7.0% passive stake in Terns Pharmaceuticals 12/23/22 Terns Pharmaceuticals director Lu acquires 758,620 common shares 12/20/22 Terns Pharmaceuticals reports inducement grants to new employees 11/04/22 Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501 MDGL Madrigal Pharmaceuticals $299.80 / -0.355 (-0.12%) 01/06/23 Madrigal announces additional results from Phase 2 MAESTRO-NASH trial 12/19/22 Madrigal jumps 217% to $202.28 after NASH study hits endpoints 12/19/22 Madrigal Pharmaceuticals announces results from Phase 3 MAESTRO-NASH trial ALGS Aligos Therapeutics $1.64 / +0.18 (+12.33%) 01/05/23 Aligos on track to complete Phase 2-enabling activities in 2023 for ALG-055009 12/14/22 Aligos Therapeutics initiates dosing in ALG-125755 trial 12/08/22 Aligos presents nonclinical data for coronavirus therapeutic program 11/04/22 Aligos Therapeutics presents data for its Capsid Assembly Modulator ALGS VKTX TERN MDGL ALGS Aligos Therapeutics $1.64 / +0.18 (+12.33%) 01/06/23 Piper Sandler Aligos upgraded to Overweight at Piper after peer's 'highly encouraging' data 01/06/23 Piper Sandler Aligos Therapeutics upgraded to Overweight from Neutral at Piper Sandler 01/06/23 Jefferies Jefferies upgrades Aligos to Buy on derisking of NASH pill 01/06/23 Jefferies Aligos Therapeutics upgraded to Buy from Hold at Jefferies VKTX Viking Therapeutics $8.95 / +0.17 (+1.94%) 12/20/22 Maxim Viking Therapeutics price target raised to $15 from $10 at Maxim 12/19/22 Maxim Viking Therapeutics price target raised to $15 from $10 at Maxim 12/19/22 Raymond James Raymond James upgrades Madrigal to Market Perform after NASH data 12/19/22 BTIG Madrigal's data bodes well for Viking's de-risked VK2809, says BTIG TERN Terns Pharmaceuticals $9.12 / +0.035 (+0.39%) 12/29/22 H.C. Wainwright Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright 09/27/22 Goldman Sachs Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs 09/12/22 H.C. Wainwright Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright 03/23/22 JPMorgan Terns downgraded after 'firmly negative' data at JPMorgan MDGL Madrigal Pharmaceuticals $299.80 / -0.355 (-0.12%) 01/06/23 Canaccord Madrigal Pharmaceuticals price target raised to $296 from $270 at Canaccord 01/05/23 JMP Securities Madrigal Pharmaceuticals price target raised to $390 from $312 at JMP Securities VKTX TERN MDGL ALGS VKTX Viking Therapeutics $8.95 / +0.17 (+1.94%) 10/26/22 Viking Therapeutics reports Q3 EPS (21c), consensus (23c) 07/27/22 Viking Therapeutics reports Q2 EPS (23c), consensus (21c) TERN Terns Pharmaceuticals $9.12 / +0.035 (+0.39%) 11/09/22 Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c) MDGL Madrigal Pharmaceuticals $299.80 / -0.355 (-0.12%) 11/03/22 Madrigal Pharmaceuticals reports Q3 EPS ($4.15), consensus ($4.75) 08/04/22 Madrigal Pharmaceuticals reports Q2 EPS ($4.14) vs ($3.72) last year ALGS Aligos Therapeutics $1.64 / +0.18 (+12.33%) 11/02/22 Aligos Therapeutics reports Q3 EPS (44c), consensus (58c) 21 Dec VKTX VKTX Viking Therapeutics $8.95 / +0.17 (+1.94%) 01/02/23 Viking sued Ascletis alleging stolen trade secrets, Reuters reports VKTX TERN MDGL ALGS VKTX Viking Therapeutics $8.95 / +0.17 (+1.94%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 12/19/22 Trial success is rocketing this NASH stock higher and sinking these peers TERN Terns Pharmaceuticals $9.12 / +0.035 (+0.39%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 12/27/22 Fly Insider: Terns, Air Transport among week's notable insider trades 12/19/22 Fly Intel: After-Hours Movers MDGL Madrigal Pharmaceuticals $299.80 / -0.355 (-0.12%) 12/19/22 What You Missed On Wall Street On Monday 12/19/22 What You Missed On Wall Street This Morning ALGS Aligos Therapeutics $1.64 / +0.18 (+12.33%) 01/06/23 What You Missed On Wall Street On Friday 01/06/23 What You Missed On Wall Street This Morning VKTX MDGL VKTX Viking Therapeutics $8.95 / +0.17 (+1.94%) 01/06/23 Viking Therapeutics call volume above normal and directionally bullish MDGL Madrigal Pharmaceuticals $299.80 / -0.355 (-0.12%) 12/23/22 Largest borrow rate increases among liquid names 12/21/22 Madrigal Pharmaceuticals put volume heavy and directionally bearish 12/05/22 Madrigal Pharmaceuticals put volume heavy and directionally bearish
Hot Stocks	Suvretta Capital reports 7.0% passive stake in Terns Pharmaceuticals » 17:07 01/03/23 01/03 17:07 01/03/23 17:07 TERN Terns Pharmaceuticals $8.76 / -1.44 (-14.12%) Suvretta Capita disclosed… Suvretta Capita disclosed a 7.0% stake in Terns Pharmaceutical , which represents over 3.44M shares. The filing does not allow for activism. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly TERN Terns Pharmaceuticals $8.76 / -1.44 (-14.12%) 12/23/22 Terns Pharmaceuticals director Lu acquires 758,620 common shares 12/20/22 Terns Pharmaceuticals reports inducement grants to new employees 11/04/22 Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501 08/12/22 Terns Pharmaceuticals announces $65M oversubscribed offering TERN Terns Pharmaceuticals $8.76 / -1.44 (-14.12%) 12/29/22 H.C. Wainwright Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright 09/27/22 Goldman Sachs Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs 09/12/22 H.C. Wainwright Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright 03/23/22 JPMorgan Terns downgraded after 'firmly negative' data at JPMorgan TERN Terns Pharmaceuticals $8.76 / -1.44 (-14.12%) 11/09/22 Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c) 21 Dec TERN Terns Pharmaceuticals $8.76 / -1.44 (-14.12%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 12/27/22 Fly Insider: Terns, Air Transport among week's notable insider trades 12/19/22 Fly Intel: After-Hours Movers
On The Fly	Fly Insider: Terns Pharma, Best Buy among week's notable insider trades » 14:22 01/03/23 01/03 14:22 01/03/23 14:22 CHPT ChargePoint $9.11 / -0.425 (-4.46%) , TERN Terns Pharmaceuticals $9.38 / -0.82 (-8.04%) , GLYC GlycoMimetics $2.99 / -0.04 (-1.32%) , ATHA Athira Pharma $3.34 / +0.175 (+5.54%) , AES AES Corp. $28.24 / -0.52 (-1.81%) , CLH Clean Harbors $113.80 / -0.31 (-0.27%) , BBY Best Buy $80.22 / + (+0.00%) , BGNE BeiGene $225.27 / +5.31 (+2.41%) Welcome to "Fly Insider,"… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TERN GLYC CLH CHPT BGNE BBY ATHA AES TERN Terns Pharmaceuticals $9.38 / -0.82 (-8.04%) 12/23/22 Terns Pharmaceuticals director Lu acquires 758,620 common shares 12/20/22 Terns Pharmaceuticals reports inducement grants to new employees 11/04/22 Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501 08/12/22 Terns Pharmaceuticals announces $65M oversubscribed offering GLYC GlycoMimetics $2.99 / -0.04 (-1.32%) 09/06/22 GlycoMimetics appoints Edwin Rock, M.D. as CMO CLH Clean Harbors $113.80 / -0.31 (-0.27%) 12/22/22 COO of Clean Harbors Gerstenberg sells over $1.9M in company shares 11/02/22 Clean Harbors appoints COO Eric Gerstenberg, CFO Michael Battles as co-CEOs 11/02/22 Clean Harbors sees FY22 adjusted EBITDA $1.01B-$1.03B 10/03/22 Hudson Technologies appoints Bulgarino, Mansy to board of directors CHPT ChargePoint $9.11 / -0.425 (-4.46%) 12/06/22 Vietnam-based EV maker VinFast plans for U.S. IPO 11/08/22 Nikola, ChargePoint announce partnership 10/05/22 ChargePoint announces global charging solution CP6000 10/02/22 Fly Intel: Top five weekend stock stories BGNE BeiGene $225.27 / +5.31 (+2.41%) 12/30/22 BeiGene announces CDE acceptance of tislelizumab sBLA 12/29/22 BeiGene CEO sells $2.16M in common stock 12/13/22 BeiGene says Brukinsa shows superior efficacy versus Imbruvica in study 12/08/22 Phanes Therapeutics announces clinical supply agreement with BeiGene BBY Best Buy $80.22 / + (+0.00%) 11/22/22 Best Buy rises 9.5% 11/22/22 Best Buy jumps 8% to $76.17 after Q3 earnings beat and comps outlook update 11/22/22 Best Buy sees FY23 comparable sales down approximately 10% 11/22/22 Genesco appoints Best Buy CFO Matthew Bilunas to board ATHA Athira Pharma $3.34 / +0.175 (+5.54%) 12/21/22 Athira Pharma announces publication of fosgonimeton preclinical results 12/05/22 Athira Pharma presents preclinical data on ATH-1105 in ALS 11/29/22 Athira Pharma: Data shows fosgonimeton treatment significantly improved NfL 11/16/22 Athira Pharma presents preclinical data on HGF-MET neurotrophic system AES AES Corp. $28.24 / -0.52 (-1.81%) 12/08/22 Air Products, AES Corp. to invest $4B in new Texas green hydrogen facility 12/02/22 AES Corp. raises quarterly dividend 5% to 16.59c per share 10/11/22 AES Corp. dedicates 227 MW, 908 MWh of energy storage projects in California 08/08/22 Fluence Energy appoints Julian Nebreda as CEO, president CHPT TERN GLYC ATHA AES CLH BBY BGNE CHPT ChargePoint $9.11 / -0.425 (-4.46%) 12/22/22 Piper Sandler ChargePoint price target lowered to $13 from $16 at Piper Sandler 12/05/22 DA Davidson ChargePoint price target lowered to $18 from $20 at DA Davidson 12/02/22 R.F. Lafferty ChargePoint price target lowered to $28 from $34 at R.F. Lafferty 12/02/22 Oppenheimer ChargePoint price target lowered to $26 from $40 at Oppenheimer TERN Terns Pharmaceuticals $9.38 / -0.82 (-8.04%) 12/29/22 H.C. Wainwright Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright 09/27/22 Goldman Sachs Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs 09/12/22 H.C. Wainwright Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright 03/23/22 JPMorgan Terns downgraded after 'firmly negative' data at JPMorgan GLYC GlycoMimetics $2.99 / -0.04 (-1.32%) 08/03/22 H.C. Wainwright GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright 04/28/22 Roth MKM Roth remains bullish on GlycoMimetics after corporate updates call ATHA Athira Pharma $3.34 / +0.175 (+5.54%) 10/17/22 JMP Securities Athira upgraded to Outperform at JMP after DMC recommends study continue 10/17/22 JMP Securities Athira Pharma upgraded to Outperform from Market Perform at JMP Securities 09/28/22 Mizuho Mizuho says Biogen data will serve as catalyst for these stocks 07/06/22 Mizuho Athira Pharma initiated with a Buy at Mizuho AES AES Corp. $28.24 / -0.52 (-1.81%) 12/01/22 Argus AES Corp. price target raised to $31 from $29 at Argus 11/09/22 Citi AES Corp. price target raised to $30 from $27 at Citi 11/07/22 Susquehanna AES Corp. price target raised to $33 from $30 at Susquehanna 08/18/22 Morgan Stanley AES Corp. price target raised to $32 from $29.50 at Morgan Stanley CLH Clean Harbors $113.80 / -0.31 (-0.27%) 11/03/22 UBS Clean Harbors downgraded to Neutral from Buy at UBS 11/03/22 Baird Clean Harbors price target raised to $155 from $150 at Baird 09/02/22 Stifel Clean Harbors price target raised to $145 from $127 at Stifel 08/04/22 BMO Capital Clean Harbors price target raised to $124 from $104 at BMO Capital BBY Best Buy $80.22 / + (+0.00%) 12/19/22 Credit Suisse Best Buy initiated with a Neutral at Credit Suisse 12/14/22 BofA Best Buy downgraded to Underperform at BofA on challenging demand environment 12/14/22 BofA Best Buy downgraded to Underperform from Neutral at BofA 12/12/22 Goldman Sachs Best Buy upgraded to Neutral from Sell at Goldman Sachs BGNE BeiGene $225.27 / +5.31 (+2.41%) 11/10/22 Cowen BeiGene price target raised to $213 from $200 at Cowen 10/13/22 Guggenheim BeiGene upgraded to Buy at Guggenheim on higher conviction in Brukinsa 10/13/22 Guggenheim BeiGene upgraded to Buy from Neutral at Guggenheim 10/12/22 SVB Securities BeiGene upgraded to Outperform at SVB Securities on positive Brukinsa data TERN GLYC CLH CHPT BGNE BBY ATHA AES TERN Terns Pharmaceuticals $9.38 / -0.82 (-8.04%) 11/09/22 Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c) GLYC GlycoMimetics $2.99 / -0.04 (-1.32%) 11/09/22 GlycoMimetics reports Q3 EPS (16c), consensus (26c) 08/03/22 GlycoMimetics reports Q2 EPS (25c), consensus (28c) CLH Clean Harbors $113.80 / -0.31 (-0.27%) 11/02/22 Clean Harbors reports Q3 adjusted EPS $2.43, consensus $2.11 08/03/22 Clean Harbors sees FY22 EBITDA $975M-$1.005B 08/03/22 Clean Harbors reports Q2 EPS $2.44 consensus $1.48 CHPT ChargePoint $9.11 / -0.425 (-4.46%) 12/01/22 ChargePoint narrows FY23 revenue view to $475M-$485M from $450M-$500M 12/01/22 ChargePoint sees Q4 revenue $160M-$170M, consensus $160.91M 12/01/22 ChargePoint reports Q3 EPS (25c), consensus (19c) 12/01/22 Notable companies reporting after market close BGNE BeiGene $225.27 / +5.31 (+2.41%) 11/09/22 BeiGene reports Q3 EPS ($5.39), consensus ($4.01) 08/04/22 BeiGene reports Q2 EPS $5.56 vs. $5.23 last year BBY Best Buy $80.22 / + (+0.00%) 11/22/22 Best Buy reports Q3 EPS $1.38, consensus $1.03 11/21/22 Notable companies reporting before tomorrow's open 08/30/22 Best Buy reports Q2 EPS$1.54, consensus $1.27 ATHA Athira Pharma $3.34 / +0.175 (+5.54%) 11/10/22 Athira Pharma reports Q3 EPS (53c), consensus (63c) 08/15/22 Athira Pharma reports Q2 EPS (65c), consensus (64c) AES AES Corp. $28.24 / -0.52 (-1.81%) 11/04/22 AES Corp. sees FY22 EPS at high end of $1.55-$1.65 range, consensus $1.61 11/04/22 AES Corp. reports Q3 adjusted EPS 63c, consensus 53c 08/05/22 AES Corp. backs FY22 adjusted EPS view $1.55-$1.65, consensus $1.60 08/05/22 AES Corp. reports Q2 adjusted EPS 34c, consensus 31c 21 Dec CHPT BBY AES CHPT ChargePoint $9.11 / -0.425 (-4.46%) 10/31/22 EU looks to resolve EV subsidy dispute with the U.S , Bloomberg says 10/01/22 SPAC bubble has burst, Blue Owl Luminar still have potential, Barron's says BBY Best Buy $80.22 / + (+0.00%) 08/12/22 Best Buy cuts hundreds of jobs in stores, WSJ reports AES AES Corp. $28.24 / -0.52 (-1.81%) 08/13/22 Plug Power, Sunrun among stocks for rush to renewable energy, Barron's says 07/30/22 NextEra, five others offer safety and growth now, Barron's says TERN GLYC CHPT BGNE BBY ATHA TERN Terns Pharmaceuticals $9.38 / -0.82 (-8.04%) 12/27/22 Fly Insider: Terns, Air Transport among week's notable insider trades 12/19/22 Fly Intel: After-Hours Movers GLYC GlycoMimetics $2.99 / -0.04 (-1.32%) 11/18/22 Biotech Alert: Searches spiking for these stocks today CHPT ChargePoint $9.11 / -0.425 (-4.46%) 12/22/22 What You Missed On Wall Street On Thursday 12/22/22 What You Missed On Wall Street This Morning 12/05/22 What You Missed On Wall Street This Morning 12/02/22 What You Missed On Wall Street On Friday BGNE BeiGene $225.27 / +5.31 (+2.41%) 11/10/22 Biotech Alert: Searches spiking for these stocks today 08/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BBY Best Buy $80.22 / + (+0.00%) 12/14/22 What You Missed On Wall Street On Wednesday 12/14/22 What You Missed On Wall Street This Morning 12/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/14/22 Fly Intel: Pre-market Movers ATHA Athira Pharma $3.34 / +0.175 (+5.54%) 09/28/22 Which Alzheimer's stock may be next to jump after Biogen's 'clean’ win? 01/04/23 JPMorgan Tech/Auto Forum 01/10/23 Transformation & Sustainability Virtual Conference 01/20/23 Extended PDUFA Date for Brukinsa 01/12/23 ChargePoint CHPT BBY AES CHPT ChargePoint $9.11 / -0.425 (-4.46%) 01/03/23 Largest borrow rate increases among liquid names 12/22/22 ChargePoint Holdings put volume heavy and directionally bearish 12/21/22 Largest borrow rate increases among liquid names 12/16/22 Unusually active option classes on open December 16th BBY Best Buy $80.22 / + (+0.00%) 11/25/22 Unusually active option classes on open November 25th 11/22/22 Early notable gainers among liquid option names on November 22nd 11/22/22 Unusually active option classes on open November 22nd 11/21/22 Best Buy put volume heavy and directionally bearish AES AES Corp. $28.24 / -0.52 (-1.81%) 12/08/22 Unusually active option classes on open December 8th 08/15/22 AES Corp. call volume above normal and directionally bullish 08/05/22 Early notable gainers among liquid option names on August 5th 08/05/22 AES Corp. call buyer realizes 130% same-day gains

Over a month ago
Recommendations	Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright » 06:13 12/29/22 12/29 06:13 12/29/22 06:13 TERN Terns Pharmaceuticals $9.13 / +0.13 (+1.44%) , MDGL Madrigal Pharmaceuticals $270.59 / +9.43 (+3.61%) H.C. Wainwright analyst… H.C. Wainwright analyst Ed Arce raised the firm's price target on Terns Pharmaceuticals (TERN) to $7 from $6 and keeps a Neutral rating on the shares after the company closed an equity financing of 11.9M common shares. The analyst increased his assumed probability of success of Terns' nonalcoholic steatohepatitis program to 45% from 35% due to the "strong validation" of the THR-beta mechanism from Madrigal's (MDGL) Phase 3 MAESTRO-NASH top-line data. However, Arce maintains a Neutral rating saying the rest of Terns' pipeline is early stage. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options TERN MDGL TERN Terns Pharmaceuticals $9.13 / +0.13 (+1.44%) 12/23/22 Terns Pharmaceuticals director Lu acquires 758,620 common shares 12/20/22 Terns Pharmaceuticals reports inducement grants to new employees 11/04/22 Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501 08/12/22 Terns Pharmaceuticals announces $65M oversubscribed offering MDGL Madrigal Pharmaceuticals $270.59 / +9.43 (+3.61%) 12/19/22 Viking Therapeutics up 58% after Madrigal announces NASH trial data 12/19/22 Madrigal jumps 217% to $202.28 after NASH study hits endpoints 12/19/22 Madrigal Pharmaceuticals announces results from Phase 3 MAESTRO-NASH trial 08/31/22 Madrigal Pharmaceuticals initiates MAESTRO-NASH Outcomes study TERN MDGL TERN Terns Pharmaceuticals $9.13 / +0.13 (+1.44%) 09/27/22 Goldman Sachs Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs 09/12/22 H.C. Wainwright Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright 03/23/22 JPMorgan Terns downgraded after 'firmly negative' data at JPMorgan 03/23/22 JPMorgan Terns Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan MDGL Madrigal Pharmaceuticals $270.59 / +9.43 (+3.61%) 12/20/22 Evercore ISI Madrigal Pharmaceuticals price target raised to $325 from $175 at Evercore ISI 12/20/22 Cowen Madrigal Pharmaceuticals price target raised to $309 from $129 at Cowen 12/20/22 Canaccord Madrigal Pharmaceuticals price target raised to $270 from $151 at Canaccord 12/20/22 Oppenheimer Madrigal Pharmaceuticals price target raised to $250 from $170 at Oppenheimer TERN MDGL TERN Terns Pharmaceuticals $9.13 / +0.13 (+1.44%) 11/09/22 Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c) MDGL Madrigal Pharmaceuticals $270.59 / +9.43 (+3.61%) 11/03/22 Madrigal Pharmaceuticals reports Q3 EPS ($4.15), consensus ($4.75) 08/04/22 Madrigal Pharmaceuticals reports Q2 EPS ($4.14) vs ($3.72) last year 21 Dec TERN MDGL TERN Terns Pharmaceuticals $9.13 / +0.13 (+1.44%) 12/27/22 Fly Insider: Terns, Air Transport among week's notable insider trades 12/19/22 Fly Intel: After-Hours Movers MDGL Madrigal Pharmaceuticals $270.59 / +9.43 (+3.61%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 12/19/22 What You Missed On Wall Street On Monday 12/19/22 What You Missed On Wall Street This Morning 12/19/22 Trial success is rocketing this NASH stock higher and sinking these peers MDGL MDGL Madrigal Pharmaceuticals $270.59 / +9.43 (+3.61%) 12/23/22 Largest borrow rate increases among liquid names 12/21/22 Madrigal Pharmaceuticals put volume heavy and directionally bearish 12/05/22 Madrigal Pharmaceuticals put volume heavy and directionally bearish
On The Fly	Fly Insider: Terns, Air Transport among week's notable insider trades » 14:43 12/27/22 12/27 14:43 12/27/22 14:43 CPB Campbell Soup $57.47 / +0.18 (+0.31%) , ABC AmerisourceBergen $169.29 / -0.59 (-0.35%) , AN AutoNation $106.83 / -0.25 (-0.23%) , ATSG Air Transport Services $25.86 / -0.14 (-0.54%) , BRT BRT Apartments $19.42 / -0.11 (-0.56%) , DSGN Design Therapeutics $9.20 / -0.33 (-3.46%) , TERN Terns Pharmaceuticals $8.86 / +0.74 (+9.11%) , GRPN Groupon $7.58 / +0.31 (+4.26%) Welcome to "Fly Insider,"… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options TERN GRPN DSGN CPB BRT ATSG AN ABC TERN Terns Pharmaceuticals $8.86 / +0.74 (+9.11%) 12/23/22 Terns Pharmaceuticals director Lu acquires 758,620 common shares 12/20/22 Terns Pharmaceuticals reports inducement grants to new employees 11/04/22 Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501 08/12/22 Terns Pharmaceuticals announces $65M oversubscribed offering GRPN Groupon $7.58 / +0.31 (+4.26%) 11/07/22 Groupon still sees 15%-20% sustainable annual adjusted EBITA margins in 2023 11/07/22 Groupon sees Q4 consolidated billings roughly 51% of 2019 levels 08/09/22 Groupon: Layoffs include payroll and nonpayroll reductions 08/09/22 Groupon sees Q3 adjusted EBITDA lower than Q2 DSGN Design Therapeutics $9.20 / -0.33 (-3.46%) 12/07/22 Design Therapeutics down 33% at $8.55 after DT-216 trial data 12/07/22 Design Therapeutics reports data from single-asecending dose trial of DT-216 10/17/22 Design Therapeutics to present preclinical data on DT-216 at ICAR 2022 CPB Campbell Soup $57.47 / +0.18 (+0.31%) 12/22/22 Campbell Soup exec sells $2.12M in common stock 12/07/22 Campbell Soup CEO: The supply chain is now a 'real strength' 11/21/22 Campbell Soup announces 12-year virtual renewable power purchase agreement BRT BRT Apartments $19.42 / -0.11 (-0.56%) 12/08/22 BRT Apartments CEO buys $319K in common stock 12/06/22 BRT Apartments CEO buys $285K in common stock 10/06/22 BRT Apartments reports no damage from Hurricane Ian ATSG Air Transport Services $25.86 / -0.14 (-0.54%) 11/21/22 Air Transport Services names Paul Chase chief commercial officer 11/03/22 ATSG sees FY22 adjusted EBITDA to meet or exceed $640M AN AutoNation $106.83 / -0.25 (-0.23%) 12/12/22 AutoNation to expand after-sales business with acquisition of RepairSmith 11/15/22 AutoNation acquires 6.1% ownership stake in TrueCar 10/27/22 AutoNation to acquire four dealerships with $320M in annual revenue 10/27/22 AutoNation announces additional $1B share repurchase program ABC AmerisourceBergen $169.29 / -0.59 (-0.35%) 12/08/22 Walgreens Boots Alliance sells $1.0B in AmerisourceBergen shares 10/03/22 PetVivo announces Spryng availability through MWI Animal Health 09/27/22 Outlook, AmerisourceBergen announce strategic commercialization agreement 09/12/22 AmerisourceBergen to acquire PharmaLex, sees accretion CPB ABC AN ATSG BRT DSGN TERN GRPN CPB Campbell Soup $57.47 / +0.18 (+0.31%) 12/20/22 Morgan Stanley Campbell Soup price target raised to $57 from $56 at Morgan Stanley 12/08/22 RBC Capital Campbell Soup price target raised to $50 from $46 at RBC Capital 12/08/22 Morgan Stanley Campbell Soup price target raised to $56 from $48 at Morgan Stanley 12/08/22 Piper Sandler Campbell Soup price target raised to $55 from $46 at Piper Sandler ABC AmerisourceBergen $169.29 / -0.59 (-0.35%) 11/22/22 Credit Suisse AmerisourceBergen price target raised to $182 from $175 at Credit Suisse 11/04/22 Baird AmerisourceBergen price target raised to $195 from $188 at Baird 10/18/22 Cowen AmerisourceBergen price target lowered to $169 from $170 at Cowen 10/11/22 BofA BofA upgrades AmerisourceBergen to Buy, sees ongoing EBIT growth AN AutoNation $106.83 / -0.25 (-0.23%) 12/27/22 Morgan Stanley Used car prices still have room to decrease 'significantly,' says Morgan Stanley 11/15/22 Craig-Hallum TrueCar price target raised to $4 from $1.50 at Craig-Hallum 10/06/22 JPMorgan AutoNation downgraded to Neutral from Overweight at JPMorgan 09/09/22 BofA AutoNation price target lowered to $238 from $250 at BofA ATSG Air Transport Services $25.86 / -0.14 (-0.54%) 10/21/22 Truist Air Transport Services initiated with a Hold at Truist 10/21/22 Truist Correction: Air Transport Services initiated with a Hold at Truist 05/09/22 Cowen Air Transport Services price target raised to $40 from $31 at Cowen 02/28/22 Truist Air Transport Services price target raised to $40 from $35 at Truist BRT BRT Apartments $19.42 / -0.11 (-0.56%) 11/11/22 B. Riley BRT Apartments price target lowered to $30 from $32 at B. Riley 05/09/22 BTIG BRT Apartments assumed with a Neutral at BTIG 03/21/22 B. Riley BRT Apartments upgraded to Buy on strategic shift at B. Riley 03/21/22 B. Riley BRT Apartments upgraded to Buy from Neutral at B. Riley DSGN Design Therapeutics $9.20 / -0.33 (-3.46%) 12/08/22 RBC Capital Design Therapeutics price target lowered to $24 from $29 at RBC Capital 12/08/22 Wedbush Design Therapeutics price target lowered to $19 from $26 at Wedbush 12/07/22 Piper Sandler Design Therapeutics' DT-216 phase 1 data looks promising, says Piper Sandler 08/09/22 Wedbush Design Therapeutics price target raised to $26 from $21 at Wedbush TERN Terns Pharmaceuticals $8.86 / +0.74 (+9.11%) 09/27/22 Goldman Sachs Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs 09/12/22 H.C. Wainwright Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright 03/23/22 JPMorgan Terns downgraded after 'firmly negative' data at JPMorgan 03/23/22 JPMorgan Terns Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan GRPN Groupon $7.58 / +0.31 (+4.26%) 11/08/22 Barclays Groupon price target lowered to $6 from $10 at Barclays 08/10/22 Barclays Groupon price target lowered to $10 from $12 at Barclays 05/10/22 Wedbush Groupon price target lowered to $15 from $22 at Wedbush 05/10/22 Barclays Groupon price target lowered to $12 from $20 at Barclays TERN GRPN DSGN CPB ATSG AN ABC TERN Terns Pharmaceuticals $8.86 / +0.74 (+9.11%) 11/09/22 Terns Pharmaceuticals reports Q3 EPS (44c), consensus (52c) GRPN Groupon $7.58 / +0.31 (+4.26%) 11/07/22 Groupon reports Q3 adjusted EPS (68c), consensus (53c) 08/08/22 Groupon withdraws FY22 guidance, affirms FY23 targets. 08/08/22 Groupon reports Q2 EPS (34c), consensus (44c) DSGN Design Therapeutics $9.20 / -0.33 (-3.46%) 11/03/22 Design Therapeutics reports Q3 EPS (32c), consensus (29c) 08/08/22 Design Therapeutics reports Q2 EPS (27c), consensus (25c) CPB Campbell Soup $57.47 / +0.18 (+0.31%) 12/07/22 Campbell Soup raises FY23 adjusted EPS view to $2.90-$3.00 from $2.85-$2.95 12/07/22 Campbell Soup reports Q1 adjusted EPS $1.02, consensus 88c 12/06/22 Notable companies reporting before tomorrow's open ATSG Air Transport Services $25.86 / -0.14 (-0.54%) 11/03/22 ATSG reports Q3 adjusted EPS 60c, consensus 56c 08/04/22 Air Transport Services still sees 2022 adjusted EBIDTA $640M 08/04/22 Air Transport Services reports Q2 adjusted EPS 59c, consensus 50c AN AutoNation $106.83 / -0.25 (-0.23%) 10/27/22 AutoNation reports Q3 adjusted EPS $6.00, consensus $6.27 10/26/22 Notable companies reporting before tomorrow's open 07/21/22 AutoNation reports Q2 EPS $6.48, consensus $6.22 ABC AmerisourceBergen $169.29 / -0.59 (-0.35%) 11/03/22 AmerisourceBergen sees FY23 adjusted EPS $11.30-$11.60, consensus $11.45 11/03/22 AmerisourceBergen reports Q4 adjusted EPS $2.60, consensus $2.57 08/03/22 AmerisourceBergen raises FY22 adjusted EPS view to $10.90-$11.10 08/03/22 AmerisourceBergen reports Q3 adjusted EPS $2.62, consensus $2.56 21 Dec 09 Dec 08 Nov GRPN CPB ABC GRPN Groupon $7.58 / +0.31 (+4.26%) 08/08/22 Groupon lays off over 500 employees, TechCrunch reports CPB Campbell Soup $57.47 / +0.18 (+0.31%) 09/17/22 Constellation stock looks particularly attractive, Barron's says ABC AmerisourceBergen $169.29 / -0.59 (-0.35%) 07/05/22 McKesson, Cardinal, AmerisourceBergen not liable for WV opioid crisis, WSJ says TERN GRPN DSGN CPB BRT AN ABC TERN Terns Pharmaceuticals $8.86 / +0.74 (+9.11%) 12/19/22 Fly Intel: After-Hours Movers GRPN Groupon $7.58 / +0.31 (+4.26%) 12/03/22 Short Report: Bears growl at crypto stocks amid FTX fallout 11/19/22 Short Report: Bears feast on Root, reduce exposure in EV names 11/11/22 Short Report: Carvana, Blue Apron see bearish bets rise DSGN Design Therapeutics $9.20 / -0.33 (-3.46%) 12/08/22 What You Missed On Wall Street On Thursday 12/08/22 What You Missed On Wall Street This Morning 12/07/22 Fly Intel: After-Hours Movers CPB Campbell Soup $57.47 / +0.18 (+0.31%) 12/27/22 Fly Insider: Terns, Air Transport among week's notable insider trades 12/07/22 What You Missed On Wall Street On Wednesday 12/07/22 What You Missed On Wall Street This Morning 12/07/22 Fly Intel: Pre-market Movers BRT BRT Apartments $19.42 / -0.11 (-0.56%) 10/03/22 Fly Insider: Clear Channel, Nikola among weeks notable insider trades AN AutoNation $106.83 / -0.25 (-0.23%) 10/27/22 Fly Intel: Pre-market Movers 10/17/22 Fly Insider: Enviva, AMD among week's notable insider trades 10/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ABC AmerisourceBergen $169.29 / -0.59 (-0.35%) 10/11/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations GRPN CPB GRPN Groupon $7.58 / +0.31 (+4.26%) 12/22/22 Largest borrow rate increases among liquid names 08/16/22 Groupon call volume above normal and directionally bullish 08/08/22 Groupon options imply 14.1% move in share price post-earnings 08/08/22 Unusually active option classes on open August 8th CPB Campbell Soup $57.47 / +0.18 (+0.31%) 12/07/22 Early notable gainers among liquid option names on December 7th 09/13/22 Campbell Soup put volume heavy and directionally bearish

On The Fly

News and insights, exclusive to thefly.com

16:25	What You Missed On Wall Street On Thursday»
13:56	What Wall Street is saying about Starbucks ahead of earnings»
13:39	What Wall Street is saying about Apple ahead of earnings»
12:31	Here's what Wall Street is saying about Qualcomm ahead of earnings»
12:14	What You Missed On Wall Street This Morning»

View all On The Fly Stories »

Upcoming
Events (10)

	NAPE Summit 2023
	Las Vegas Market 2023
	NAFEM Show 2023
	20th Annual Infrastructure & Utilities Conference
FRPT ...	Groundhog Day Investment Forum 2023
	ABA Derivatives and Futures Law Committee Winter Meeting
	International Builders Show: IBS 2023
INSE	Inspired Entertainment
ACHV	Achieve Life Sciences
LTH	Life Time Group

View all of today’s events »

Today’s
Syndicate (3)

ALGM	Block Trade
VERA	Spot Secondary
WULF	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial